Rydex Biotechnology Fund Class C (RYCFX)
| Fund Assets | 115.29M |
| Expense Ratio | 2.40% |
| Min. Investment | $2,500 |
| Turnover | 75.00% |
| Dividend (ttm) | 9.41 |
| Dividend Yield | 20.28% |
| Dividend Growth | -0.18% |
| Payout Frequency | n/a |
| Ex-Dividend Date | Dec 16, 2025 |
| Previous Close | 46.37 |
| YTD Return | 8.63% |
| 1-Year Return | 41.94% |
| 5-Year Return | 22.49% |
| 52-Week Low | 39.45 |
| 52-Week High | 53.71 |
| Beta (5Y) | 0.70 |
| Holdings | 75 |
| Inception Date | Mar 30, 2001 |
About RYCFX
Rydex Biotechnology Fund Class C is an open-end mutual fund focused on the biotechnology sector within the broader healthcare industry. Its primary objective is to achieve capital appreciation by investing primarily in companies involved in biotechnology, including firms engaged in research, development, and commercialization of innovative medical products and technologies. The fund holds a portfolio of approximately 78 securities, with a significant, though not exclusive, concentration in biotechnology firms, making it sensitive to developments and trends within the sector. The fund is team-managed and overseen by Security Investors, LLC, and it is designed for investors seeking exposure to the growth potential of biotechnology and related healthcare companies. It periodically distributes income and capital gains, with an expense ratio that reflects the specialized nature of the strategy. Rydex Biotechnology Fund Class C plays a distinctive role in the market by offering targeted access to a dynamic segment often associated with innovation in pharmaceuticals, medical devices, and genetic engineering, appealing to those interested in thematic sector investing.
Performance
RYCFX had a total return of 41.94% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.66%.
Equivalent Funds
These are funds that follow the same index from the other major fund companies.
| Symbol | Provider | Name | Expense Ratio |
|---|---|---|---|
| FIKCX | Fidelity | Fidelity Advisor Health Care Fund - Class Z | 0.56% |
| FSPHX | Fidelity | Fidelity Select Health Care Portfolio | 0.62% |
| FIJYX | Fidelity | Fidelity Advisor Biotechnology Fund - Class Z | 0.58% |
| FACDX | Fidelity | Fidelity Advisor Health Care Fund - Class A | 0.93% |
| FSHCX | Fidelity | Fidelity Select Health Care Services Portfolio | 0.67% |
Top 10 Holdings
36.66% of assets| Name | Symbol | Weight |
|---|---|---|
| AbbVie Inc. | ABBV | 7.39% |
| Amgen Inc. | AMGN | 5.23% |
| Gilead Sciences, Inc. | GILD | 4.96% |
| Vertex Pharmaceuticals Incorporated | VRTX | 4.01% |
| Regeneron Pharmaceuticals, Inc. | REGN | 3.56% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.60% |
| Insmed Incorporated | INSM | 2.45% |
| BeOne Medicines AG | ONC | 2.29% |
| Natera, Inc. | NTRA | 2.09% |
| United Therapeutics Corporation | UTHR | 2.07% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 16, 2025 | $9.40578 | Dec 16, 2025 |
| Dec 12, 2024 | $9.42277 | Dec 12, 2024 |
| Dec 20, 2022 | $0.89943 | Dec 20, 2022 |
| Dec 8, 2021 | $15.77303 | Dec 8, 2021 |
| Dec 9, 2020 | $6.95038 | Dec 9, 2020 |
| Dec 10, 2019 | $3.60206 | Dec 10, 2019 |